Published in Lancet on May 13, 1989
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis (2007) 3.89
Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis (2003) 3.33
Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis (1992) 2.26
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum (2013) 1.80
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis (2001) 1.78
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis (2006) 1.77
Radiologic observation: repair of focal bone erosions after humanized antitumor necrosis factor antibody adalimumab therapy in a patient with rheumatoid arthritis. Clin Rheumatol (2009) 1.66
Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis (2003) 1.54
The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes (2009) 1.52
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis (2013) 1.45
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis (1999) 1.44
Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis (2002) 1.38
Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther (2010) 1.38
Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis (2001) 1.37
Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis (2004) 1.29
Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis (2003) 1.26
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis (2007) 1.25
Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther (2008) 1.22
Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis (2007) 1.18
A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis (2004) 1.17
Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis (2006) 1.16
Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) (2010) 1.14
Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. Ann Rheum Dis (2000) 1.13
Should patients with recent onset rheumatoid arthritis be offered genetic screening? Ann Rheum Dis (1996) 1.11
Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis (2000) 1.08
Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient? Ann Rheum Dis (1993) 1.08
Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis. Ann Rheum Dis (1998) 1.07
Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther (2006) 1.04
Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis. Arthritis Res Ther (2007) 1.00
Radiographic severity of rheumatoid arthritis in African Americans: results from a multicenter observational study. Arthritis Care Res (Hoboken) (2010) 0.98
Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis (2001) 0.98
Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine. Ann Rheum Dis (1992) 0.97
Medical management of rheumatoid arthritis. BMJ (1993) 0.96
Mutual antagonism of rheumatoid arthritis and hay fever; a role for type 1/type 2 T cell balance. Ann Rheum Dis (1998) 0.95
Interpreting radiographic data in rheumatoid arthritis. Ann Rheum Dis (2003) 0.94
Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporos Int (2012) 0.93
Rheumatoid factor measured by fluoroimmunoassay: a responsive measure of rheumatoid arthritis disease activity that is associated with joint damage. Ann Rheum Dis (2002) 0.93
Baseline anti-citrullinated peptide antibody (ACPA) titers and serum interleukin-6 (IL-6) levels possibly predict progression of bone destruction in early stages of rheumatoid arthritis (ERA). Rheumatol Int (2012) 0.92
A T cell receptor beta chain variable region polymorphism associated with radiographic progression in rheumatoid arthritis. Ann Rheum Dis (1993) 0.92
A critical appraisal of radiographic scoring systems for assessment of juvenile idiopathic arthritis. Pediatr Radiol (2006) 0.92
Molecular mechanisms of sulfasalazine-induced T-cell apoptosis. Br J Pharmacol (2002) 0.91
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology (2015) 0.89
Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis. BMC Musculoskelet Disord (2011) 0.89
Anti-TNF agents for rheumatoid arthritis. Br J Clin Pharmacol (2001) 0.88
Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis. Ann Rheum Dis (1992) 0.88
Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 0.87
Outcome of second line therapy in rheumatoid arthritis. Ann Rheum Dis (1994) 0.86
The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis (2015) 0.86
An overview of commonly used radiographic scoring methods in rheumatoid arthritis clinical trials. Clin Rheumatol (2010) 0.85
Disease modifying drugs for rheumatoid arthritis: yesterday's treatment today or today's treatment tomorrow? Br J Clin Pharmacol (1990) 0.85
Joint surgery in the Utrecht Rheumatoid Arthritis Cohort: the effect of treatment strategy. Ann Rheum Dis (2006) 0.84
Association of IL4R single-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis. Arthritis Res Ther (2010) 0.83
A vital clue to deciphering bone pathology: MRI bone oedema in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis (2007) 0.82
The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial. Arthritis Res Ther (2011) 0.80
Bone marrow edema and osteitis in rheumatoid arthritis: the imaging perspective. Arthritis Res Ther (2012) 0.80
Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study. Clin Rheumatol (2011) 0.80
HLA-DMA*0103 and HLA-DMB*0104 alleles as novel prognostic factors in rheumatoid arthritis. Ann Rheum Dis (2004) 0.80
Clinical approaches to early inflammatory arthritis. Nat Rev Rheumatol (2009) 0.80
Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate. Int J Rheumatol (2013) 0.79
Very recent onset arthritis: the value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Rheumatol (2009) 0.79
MRI osteitis predicts cartilage damage at the wrist in RA: a three-year prospective 3T MRI study examining cartilage damage. Arthritis Res Ther (2014) 0.79
Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. RMD Open (2016) 0.78
Exploring cartilage damage in gout using 3-T MRI: distribution and associations with joint inflammation and tophus deposition. Skeletal Radiol (2014) 0.78
Certolizumab pegol: a new biologic targeting rheumatoid arthritis. Expert Rev Clin Immunol (2010) 0.78
Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. Arthritis Res Ther (2016) 0.78
Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides. Arthritis Res Ther (2015) 0.78
Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans. Arthritis Res Ther (2016) 0.78
Flexor Hallucis Longus tendon rupture in RA-patients is associated with MTP 1 damage and pes planus. BMC Musculoskelet Disord (2007) 0.77
Reporting of radiographic methods in randomised controlled trials assessing structural outcomes in rheumatoid arthritis. Ann Rheum Dis (2006) 0.77
Rheumatoid arthritis. BMJ Clin Evid (2007) 0.77
Structural damage in rheumatoid arthritis as visualized through radiographs. Arthritis Res (2002) 0.77
Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis. RMD Open (2016) 0.76
Course of damage to the hallux over 5 years after forefoot resection arthroplasty in rheumatoid arthritis patients. Int Orthop (2006) 0.76
Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis. Ann Rheum Dis (2007) 0.76
Evidence for early disease-modifying drugs in rheumatoid arthritis. Arthritis Res Ther (2003) 0.76
Predictor of Hand Radiological Progression in Patients With Rheumatoid Arthritis Receiving TNF Antagonist Therapy by Change in Grayscale Synovitis-A Preliminary Study. J Clin Rheumatol (2017) 0.75
Asymptomatic atherosclerosis in egyptian rheumatoid arthritis patients and its relation to disease activity. Int J Rheumatol (2015) 0.75
The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life. Open Access Rheumatol (2009) 0.75
Low dose desensitisation does not reduce the toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis (1996) 0.75
Combination chemotherapy in rheumatoid arthritis. Ann Rheum Dis (1991) 0.75
Disease assessment in rheumatoid arthritis. Ann Rheum Dis (1989) 0.75
Multireader assessment as an alternative to reference assessment to improve the detection of radiographic progression in a large longitudinal cohort of rheumatoid arthritis (ESPOIR). RMD Open (2017) 0.75
Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. Rheumatology (Oxford) (2015) 0.75
Certolizumab in the long-term treatment of rheumatoid arthritis. Open Access Rheumatol (2011) 0.75
Managing rheumatic and musculoskeletal diseases - past, present and future. Nat Rev Rheumatol (2017) 0.75
The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskelet Disord (2016) 0.75
Discontinuation of etanercept in patients with rheumatoid arthritis who were in clinical remission. Clin Rheumatol (2009) 0.75
Assessment of 3-month changes in bone microstructure under anti-TNFα therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT). Arthritis Res Ther (2017) 0.75
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis (1990) 5.49
Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum (1998) 5.40
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol (1993) 4.62
The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2000) 4.10
Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol (1994) 3.50
The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum (2001) 3.47
Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol (1996) 3.36
Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum (1992) 3.05
ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol (1999) 2.58
Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf (1997) 2.30
Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol (1992) 2.29
Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis (1992) 2.26
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl (1994) 2.23
Glucocorticosteroids in the management of rheumatoid arthritis. Rheumatology (Oxford) (1999) 2.19
[Medical scientific research with people: what the law does not regulate]. Ned Tijdschr Geneeskd (1999) 2.00
Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy. Br J Rheumatol (1992) 1.82
Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med (1993) 1.80
Bone mass in patients with rheumatoid arthritis. Ann Rheum Dis (1992) 1.77
IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression? Scand J Rheumatol (1995) 1.76
A Dutch version of the functional index for ankylosing spondylitis: development and validation in a long-term study. Br J Rheumatol (1994) 1.73
Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity. Ann Rheum Dis (1993) 1.61
Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum (1988) 1.61
Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol (1993) 1.57
No support for HLA-DQ encoded susceptibility in rheumatoid arthritis. Arthritis Rheum (1999) 1.54
Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol (1995) 1.53
IgA serum levels and disease activity in ankylosing spondylitis: a prospective study. Ann Rheum Dis (1985) 1.49
Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) (1999) 1.44
Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol (1997) 1.44
Familial vs sporadic rheumatoid arthritis (RA). A prospective study in an early RA inception cohort. Rheumatology (Oxford) (2000) 1.41
No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis (2000) 1.40
Use of diuretics and opportunities for withdrawal in a Dutch nursing home population. Neth J Med (1998) 1.39
Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol (1993) 1.39
[Pharmacotherapy of patients with (early) rheumatoid arthritis]. Ned Tijdschr Geneeskd (2000) 1.39
Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs. sulphasalazine. Scand J Rheumatol (1990) 1.37
Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis (1994) 1.37
Pharmacovigilance in perspective. Drug Saf (1999) 1.36
Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis (2001) 1.35
Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis (2005) 1.35
Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol (1997) 1.34
Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis (1999) 1.33
The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol (1993) 1.33
Health Assessment Questionnaire modifications: is standardisation needed? Ann Rheum Dis (2001) 1.33
Principles of signal detection in pharmacovigilance. Drug Saf (1997) 1.31
Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Intern Med (1994) 1.29
Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis. J Rheumatol (2001) 1.28
Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis. Br J Rheumatol (1992) 1.28
Radiographic damage in large joints in early rheumatoid arthritis: relationship with radiographic damage in hands and feet, disease activity, and physical disability. Br J Rheumatol (1997) 1.27
Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum (2001) 1.26
Influence of non-steroidal anti-inflammatory drugs on diuretic treatment of mild to moderate essential hypertension. Br Med J (Clin Res Ed) (1984) 1.17
Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Br J Rheumatol (1995) 1.13
Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. J Rheumatol (1991) 1.10
Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up. Lancet (1990) 1.09
Contribution of inappropriate treatment for hypertension to pathogenesis of stroke in the elderly. Br Med J (Clin Res Ed) (1986) 1.09
Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis (2000) 1.08
Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br J Rheumatol (1994) 1.08
Long-term second-line treatment: a prospective drug survival study. Br J Rheumatol (1992) 1.06
Loose stools during auranofin treatment: clinical study and some pathogenetic possibilities. J Rheumatol (1983) 1.04
Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation. Br J Clin Pharmacol (1987) 1.01
Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann Rheum Dis (1995) 1.00
Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis (2001) 0.98
A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis (1989) 0.97
Comparison of auranofin and aurothioglucose in the treatment of rheumatoid arthritis: a single blind study. Clin Rheumatol (1984) 0.97
Drug use and adverse drug reactions in 105 elderly patients admitted to a general medical ward. Neth J Med (1994) 0.97
Mechanisms of drug transfer across the human placenta. Pharm World Sci (1998) 0.95
Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis (1995) 0.94
Association of HLA antigens, toxic reactions and therapeutic response to auranofin and aurothioglucose in patients with rheumatoid arthritis. Tissue Antigens (1983) 0.93
[Proceedings: Double-blind comparison of MK 231 with indomethacin in spondylitis ankylopoetica]. Ned Tijdschr Geneeskd (1975) 0.93
Cross-sectional study of rheumatoid arthritis treatment in a university hospital. Ann Rheum Dis (1985) 0.93
A T cell receptor beta chain variable region polymorphism associated with radiographic progression in rheumatoid arthritis. Ann Rheum Dis (1993) 0.92
Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. J Rheumatol (2001) 0.91
The effects of sulindac and indomethacin on the anti-hypertensive and diuretic action of hydrochlorothiazide in patients with mild to moderate essential hypertension. Br J Clin Pharmacol (1986) 0.91
Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs). Baillieres Clin Rheumatol (1997) 0.91
Genetic anticipation in rheumatoid arthritis in Europe. European Consortium on Rheumatoid Arthritis Families. J Rheumatol (2001) 0.91
Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers. Clin Pharmacol Ther (1992) 0.90
Grand rounds in rheumatology: acute rheumatic fever or post-streptococcal reactive arthritis: a clinical problem revisited. Br J Rheumatol (1998) 0.90
Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J Rheumatol (1993) 0.88
Radiographic progression in rheumatoid arthritis: results of 3 comparative trials. J Rheumatol (1995) 0.87
Familial aggregation of rheumatoid arthritis in The Netherlands: a cross-sectional hospital-based survey. European Consortium on Rheumatoid Arthritis families (ECRAF). Rheumatology (Oxford) (1999) 0.86
Hypersensitivity to ethambutol. Tubercle (1981) 0.86
Cognitive, behavioral and physiological reactivity to pain as a predictor of long-term pain in rheumatoid arthritis patients. Pain (2001) 0.86
Influence of a ceiling effect on the assessment of radiographic progression in rheumatoid arthritis during the first 6 years of disease. J Rheumatol (1999) 0.86
Early treatment of rheumatoid arthritis: rationale, evidence, and implications. Ann Rheum Dis (1998) 0.86
Area under the curve for the American College of Rheumatology improvement criteria: a valid addition to existing criteria in rheumatoid arthritis? Arthritis Rheum (2001) 0.85
Validity and reproducibility of self-administered joint counts. A prospective longitudinal followup study in patients with rheumatoid arthritis. J Rheumatol (1996) 0.85
Loop diuretics in patients aged 75 years or older: general practitioners' assessment of indications and possibilities for withdrawal. Eur J Clin Pharmacol (1998) 0.85
Serum IgA and gold-induced toxic effects in patients with rheumatoid arthritis. Arch Intern Med (1984) 0.85
Is dose adjustment of non-steroidal anti-inflammatory drugs necessary in the elderly? A review of the pharmacokinetics of NSAID in the aged. Neth J Med (1987) 0.84
Comparison of steady-state serum concentrations of digoxin in tablets (Lanoxin) and capsules (Lanoxicaps) in the elderly. DICP (1991) 0.84
Absorption of high dose furosemide (frusemide) in congestive heart failure. Clin Pharmacokinet (1992) 0.84
The influence of ibuprofen, diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide. Eur J Clin Pharmacol (1987) 0.83